Carregant...
Safety of Intravenous Iron in Hemodialysis Patients
Among end-stage renal disease patients maintained by hemodialysis, anemia has been managed primarily through erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron. Following concerns about the cardiovascular safety of ESAs and changes in the reimbursement policies in Medicare’s ESRD pro...
Guardat en:
| Publicat a: | Hemodial Int |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5517096/ https://ncbi.nlm.nih.gov/pubmed/28370957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hdi.12558 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|